Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 47Terminated 4Withdrawn 3Recruiting 3Active not recruiting 2Unknown 1Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Small Cell Lung Carcinoma 1Lung Cancer Metastatic 1Breast Neoplasms 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × MLN 8237 × Clear all
NCT06095505 2026-02-17

ALISCA-Lung1

Puma Biotechnology, Inc.

Phase 2 Recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06369285 2025-12-10

ALISCA-Breast1

Puma Biotechnology, Inc.

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT04085315 2024-06-10

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

University of California, San Francisco

Phase 1 Recruiting
38 enrolled
Thoracic

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡